There are important differences among guideline recommendations for using statin therapy in primary prevention. New recommendations from the US Preventive Services Task Force (USPSTF) emphasize therapy based on the presence of 1 or more cardiovascular disease (CVD) risk factors and a 10-year global CVD risk of 10% or greater.
I n 2013, the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines substantially expanded the population eligible for statin therapy by basing recommendations on an elevated 10-year risk of atherosclerotic cardiovascular disease (ASCVD). 1, 2 In 2016, the US Preventive Services Task Force (USPSTF) released new recommendations for primary prevention statin therapy that increased the estimated ASCVD risk threshold for patients (including those with diabetes) and required the presence of at least 1 cardiovascular risk factor (ie, hypertension, diabetes, dyslipidemia, or smoking) in addition to elevated risk. 3 This study used data from the National Health and Nutrition Examination Survey (NHANES) to compare the proportion of individuals in the United States who would be eligible for primary prevention statin treatment with the 2016 USPSTF recommendations compared with the 2013 ACC/AHA guideline recommendations.
Methods
For this analysis, we used data from the 2009-2014 fasting subsample of the continuous NHANES, which contains a representative sample of the US civilian noninstitutionalized population. 4 We excluded persons younger than 40 years or older than 75 years, those with a history of cardiovascular disease (CVD) (defined as symptomatic coronary artery disease or ischemic stroke), those with a triglyceride level greater than 400 mg/dL (4.52 mmol/L), and those with missing values for low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, total cholesterol, or systolic blood pressure.
We assessed eligibility for statin therapy according to the criteria outlined in the USPSTF recommendations 3 We determined the proportion of adults eligible for statin therapy under each recommendation following NHANES analytic guidelines, using sample weights to account for the complex multistage probability-sampling design, nonresponse rates, and oversampling of certain segments of the population. 6, 7 Adults with LDL-C levels of 190 mg/dL (4.92 mmol/L) or greater and those who reported use of lipidlowering medications were considered "recommended," because pretreatment lipid levels were unavailable. We examined clinical characteristics and average ASCVD risk 8, 9 of individuals with concordant and discordant recommendations by the 2 guidelines in the overall sample and by age group (40-59 years and 60-75 years). We also investigated the reasons some individuals would no longer meet eligibility for treatment recommendation when transitioning from ACC/AHA guidelines to USPSTF recommendations. Analyses were performed using SAS version 9.4 (SAS Institute Inc). All individuals provided informed consent to participate in the NHANES study. The NHANES survey data are available publically, and the survey has been approved by the National Center for Health Statistics ethics review board. The analyses reported in this article were considered exempt by the Duke University institutional review board (PRO00078278).
Results
After exclusion of 577 individuals (13.6%) with CVD, 66 (1.6%) with triglyceride levels greater than 400 mg/dL (4.52 mmol/L), and 175 (4.1%) with missing laboratory or blood pressure data, the study sample consisted of 3416 adults aged 40 to 75 years, free of CVD with triglyceride levels of 400 mg/dL or less. 
Key Points
Question How do the 2016 USPSTF primary prevention statin recommendations compare with the ACC/AHA 2013 guidelines in terms of the proportion of US adults potentially treated?
Findings Using estimates based on data from 3416 participants in the 2009-2014 NHANES, the USPSTF recommendations would be associated with statin initiation in 16% of US adults aged 40 to 75 years without prior cardiovascular disease (CVD), compared with 24% according to the ACC/AHA guidelines. Of the 8.9% of adults who would no longer be recommended to receive therapy under the USPSTF recommendations, 55% are aged 40 to 59 years with a mean 30-year cardiovascular risk exceeding 30%, and 28% have diabetes.
Meaning Compared with the 2013 ACC/AHA guidelines, adherence to the 2016 USPSTF recommendations could lead to a lower number of individuals recommended for primary prevention statin therapy, including many younger adults with high mean long-term CVD risk. Further examination of individuals with diabetes not already taking lipid-lowering therapy revealed that, among older adults (60-75 years), the proportions recommended for statins would be similar under both the USPSTF recommendations and the ACC/AHA guidelines: 2.3% (95% CI, 1.7%-2.9%) and 2.5% (95% CI, 1.9%-3.1%) of the primary prevention population, respectively (Table 1) . However, among younger individuals (40-59 years), the USPSTF recommendations would recommend statins for 42% of those recommended for statins under the ACC/AHA guidelines (representing 1.6% [95% CI, 1.1%-2.1%] vs 3.8% [95% CI, 3.0%-4.6%] of the primary prevention population). Table 2 shows reasons that the 8.9% of individuals with an ACC/AHA recommendation for lipid-lowering therapy would no longer be recommended for statins according to the USPSTF guidelines. These include (1) adults free of diabetes and with 10-year risk of 7.5% to 10.0% (5.3% of the primary prevention population [95% CI, 4.4%-6.2%]), primarily men with high rates of smoking, dyslipidemia, and high median LDL-C levels; (2) adults with diabetes and LDL-C levels of 70 mg/dL (1.81 mmol/L) or greater and with a 10-year risk less than 10% (2.5% of the primary prevention population [95% CI, 1.9%-3.1%]), primarily younger women with high rates of obesity; and (3) adults with 10-year risk 10% or greater but no cardiovascular risk factor defined by the USPSTF recommendations (ie, hypertension, diabetes, dyslipidemia, or smoking) (1.1% of the primary prevention population [95% CI, 0.7%-1.5%]), generally older men with lower median LDL-C levels.
Discussion
In this study based on NHANES participants from 2009-2014, it was estimated that, if fully implemented, the USPSTF recommendations would be associated with statin initiation in 15.8% of US adults aged 40 to 75 years without prior CVD, in addition to the 21.5% of adults already taking lipid-lowering therapy; in comparison, the ACC/AHA guidelines would be associated with statin initiation in an additional 24.3%. If these estimates are accurate and assuming these proportions can be projected to the US population, there could be an estimated 17.1 million vs 26.4 million US adults with a new recommendation for statin therapy, based on the USPSTF recommendations vs the ACC/AHA guideline recommendations, respectively-an estimated difference of 9.3 million individuals. Further exploration of those who are be considered. This study should be interpreted in light of several caveats and limitations. First, the analysis depends on the representativeness and accuracy of NHANES data, which in part relies on self-report. Second, it is not possible to accurately determine the effects of new recommendations for individuals currently receiving lipid-lowering therapy. Third, the analysis did not take into account the controversy that exists over whether the ASCVD risk score overestimates risk in certain subgroups. 12 Fourth, this analysis was based on a crosssectional sample that does not account for changes in risk and treatment patterns over time. Fifth, the study assumed that treatment recommendation equated with treatment initiation, whereas USPSTF recommendations and ACC/AHA guidelines also recommend an informed risk-benefit discussion between patients and clinicians.
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Conclusions
In this sample of US adults from 2009-2014, adherence to the 2016 USPSTF recommendations for statin therapy, compared with the 2013 ACC/AHA guidelines, could lead to a lower number of individuals recommended for primary prevention statin therapy, including many younger adults with high mean longterm CVD risk.
